Open AccessTriple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report
Author(s) -
Xuyan Hu,
Yu-Cheng Fei,
Wenchao Zhou,
Jinmiao Zhu,
Donglai Lv
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i11.2627
Subject(s) - medicine , osimertinib , adenocarcinoma , chemotherapy , lung , administration (probate law) , lung cancer , oncology , general surgery , surgery , cancer , ros1 , political science , law
Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). However, primary or acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) seems inevitable, and when drug-resistance occurs during treatment with osimertinib, the standard of care is to discontinue the TKI.